Role of taxoids in head and neck cancer

Oncologist

Volumn 5, Issue 3, 2000, Pages 199-208

  Schrijvers, D ^a   Vermorken, J B ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Combination chemotherapy; Docetaxel; Head and neck cancer; Paclitaxel; Radiotherapy

Indexed keywords

ANTIMETABOLITE; CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; NAVELBINE; PACLITAXEL; TAXOID;

ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL DEATH; CLINICAL TRIAL; CYTOTOXICITY; DRUG MECHANISM; DRUG STRUCTURE; HEAD AND NECK CANCER; HUMAN; MICROTUBULE; MITOSIS; MULTIMODALITY CANCER THERAPY; NEUROTOXICITY; PRIORITY JOURNAL;

EID: 0033934622     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.5-3-199     Document Type: Article

References (65)

1. Eisenhauer EA, Vermorken JB. The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs 1998;55:5-30.
2. Basu A, Haldar S. The relationship between Bcl-2, Bax and p53: consequences for cell cycle progression and cell death. Mol Hum Reprod 1998;4:1099-1109.
3. Kawakami K, Tsukuda M, Mizuno H et al. Alteration of the Bcl-2/bax status of head and neck cancer cell lines by chemotherapeutic agents. Anticancer Res 1999;19:3927-3932.
4. Gan Y, Wientjes MG, Schuller DE et al. Pharmacodynamics of Taxol in human head and neck tumors. Cancer Res 1996;56:2086-2093.
5. Pulkkinen J, Elomaa L, Joensuu H et al. Paclitaxel-induced apoptotic changes followed by time-lapse video microscopy in cell lines established from head and neck cancer. J Cancer Res Clin Oncol 1996;122:214-218.
6. Lin HL, Liu TY, Wu CW et al. Berberine modulates expression of mdrl gene product and the responses of digestive track [sic] cancer cells to paclitaxel. Br J Cancer 1999;81:416-422.
7. Dunphy C, Dunphy F, Boyd J et al. Expression of p53 protein in advanced head and neck squamous cell carcinoma before and after chemotherapy. Arch Otolaryngol Head Neck Surg 1997;123:1223-1225.
8. Nielsen L, Lipari P, Dell J et al. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Clin Cancer Res 1998;4:835-846.
9. Griffon EG, Merlin JL, Marchal C. In vitro evaluation of Taxol combined with radiation in human squamous cell carcinoma spheroids. Cancer Lett 1996;109:23-32.
10. Leonard CE, Chan DC, Chou TC et al. Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck. Cancer Res 1996;56:5198-5204.
11. Pradier O, Laurent D, Schmidberger H et al. In vitro study of paditaxel-radiotherapy combination on a human epidermoid tumor cell line. Cancer Radiother 1999;3:51-56.
12. Smith R, Thornton D, Allen J. A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative studies. Semin Oncol 1995;22:41-46.
13. Gebbia V, Testa A, Cannata G et al. Single agent paclitaxel in advanced squamous cell head and neck carcinoma. Eur J Cancer 1996;32:901-902.
14. Forastiere A, Shank D, Neuberg D et al. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer 1998;82:2270-2274.
15. Vermorken JB, Catimel G, De Mulder P et al. Randomized phase II trial of weekly methotrexate versus two schedules of three-weekly paclitaxel (Taxol®) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 1999;18:395a.
16. Frasci G, Comella P, Parziale A et al. Cisplatin-paclitaxel weekly schedule in advanced solid tumors: a phase I study. Ann Oncol 1997;8:291-293.
17. Licitra L, Capri G, Fulfaro F et al. Biweekly paclitaxel and cisplatin in patients with advanced head and neck carcinoma. A phase II trial. Ann Oncol 1997;8:1157-1158.
18. Schilling T, Heinrich B, Kau R et al. Paclitaxel administered over 3 h followed by cisplatin in patients with advanced head and neck squamous cell carcinoma: a clinical phase I study. Oncology 1997;54:89-95.
19. Hitt R, Hornedo J, Colomer R et al. Study of escalating doses of paclitaxel plus cisplatin in patients with inoperable head and neck cancer. Semin Oncol 1997;24(suppl 2):58-64.
20. Thodtmann F, Theiss F, Kemmerich M et al. Clinical phase II evaluation of paclitaxel in combination with cisplatin in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol 1998;9:335-337.
21. Adamo V, Maisano R, Laudani A et al. Phase II study paclitaxel and cisplatin in advanced and recurrent head and neck cancer. Eur J Cancer 1999;35(suppl 4):178.
22. Benasso M, Numico G, Rosso R et al. Chemotherapy for relapsed head and neck cancer: paclitaxel, cisplatin, and 5-fluorouracil in chemotherapy-naive patients. A dose-finding study. Semin Oncol 1997;24(suppl 19):46-50.
23. Hitt R, Brandariz A, Paz-Ares L et al. A Phase II study of paclitaxel, cisplatin and 5-fluorouracil in locally advanced head and neck cancer. Proc Am Soc Clin Oncol 1998;17:382a.
24. Shin DM, Glisson BS, Khuri FR et al. Phase II trial of paclitaxel. ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998;16:1325-1330.
25. Kosmas C, Tsavaris NB, Polyzos A et al. Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours. Br J Cancer 2000;82:300-307.
26. Dunphy FR, Boyd JH, Kim HJ et al. A phase I report of paclitaxel dose escalation combined with a fixed dose of carboplatin in the treatment of head and neck carcinoma. Cancer 1997;79:2016-2023.
27. Fountzilas G, Skarlos D. Athanassiades A et al. Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck. A phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 1997;8:451-455.
28. Stathopoulos G, Rigatos S, Papakostas P et al. Effectiveness of paclitaxel and carboplatin combination in heavily pretreated patients with head and neck cancers. Eur J Cancer 1997;33:1780-1783.
29. Junor E, Paul J, Robertson A et al. Phase I dose finding study of paclitaxel in combination with carboplatin in advanced and recurrent squamous carcinoma of the head and neck. Proc Am Soc Clin Oncol 1999;18:407a.
30. Huber M, Lee J, Newman R et al. A phase I investigation of the sequential use of methotrexate and paclitaxel with and without G-CSF for the treatment of solid tumors. Ann Oncol 1996;7:59-63.
31. Constenla-Figueiras M, Mel-Lorenzo JR, Garcia-Arroyo FR et al. A phase II study of weekly 1 hour paclitaxel (T) and 24-hour infusion with high-dose fluorouracil (5-FU) with leucovorin (LV) for advanced carcinoma of the head and neck. Ann Oncol 1996;7(suppl 5):80.
32. Rothenberg M, Eckhardt J, Weiss G et al. Preliminary results of a phase I trial of gemcitabine and paclitaxel in patients with refractory solid tumors. Recent clinical advantages with Gemzar. ASCO satellite symposium 1997;3:11-14.
33. Fountzilas G, Stathopoulos G, Nicolaides C et al. Paclitaxel and gemcitabine in advanced non-nasopharyngeal head and neck cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 1999;10:475-478.
34. Plasswilm L, Kirschner M, Sauer R. Concurrent Taxol and split-course accelerated radiotherapy for advanced head and neck cancer. Strahlenther Onkol 1996;172:573-579.
35. Hoffmann W, Belka C, Schmidberger H et al. Radiotherapy and concomitant weekly 1-hour infusion of paclitaxel in the treatment of head and neck cancer. Results from a phase I trial. Int J Radiat Oncol Biol Phys 1997;38:691-696.
36. Tishler RB, Busse PM, Norris C et al. An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies. Int J Radiat Oncol Biol Phys 1999;43:1001-1008.
37. Steinberg L, Hassan M, Olmsted L et al. A phase I trial of radiotherapy and simultaneous 24-hour paclitaxel in patients with locally advanced head and neck squamous cell carcinoma. Semin Oncol 1997;24(suppl 19):51-56.
38. Dowell J, Sinard R, Yardley D et al. Seven-week continuous-infusion paclitaxel concurrent with radiation therapy for locally advanced non-small cell lung and head and neck cancers. Semin Radiat Oncol 1999;2(suppl 1):97-101.
39. Conley B, Jacobs M, Suntharalingam M et al. A pilot trial of paclitaxel, carboplatin, and concurrent radiotherapy for unresectable squamous cell carcinoma of the head and neck. Semin Oncol 1997;24(suppl 2):78-80.
40. Chougule P, Akhtar M, Akerley W et al. Chemoradiotherapy for advanced inoperable head and neck cancer. A phase II study. Semin Radiat Oncol 1999;9(suppl 1):58-63.
41. Eckhardt A, Wildfang I, Karstens J. Simultaneous radiochemotherapy with Taxol/carboplatin in advanced operable head and neck tumors. Preliminary results. Strahlenther Onkol 1999;175(suppl 3):11-13.
42. Hainsworth J, Meluch A, Greco F. Paclitaxel, carboplatin, and long-term continuous 5-fluorouracil infusion in the treatment of upper aerodigestive malignancies: preliminary results of phase II trial. Semin Oncol 1997;24(suppl 19):38-42.
43. Brockstein B, Haraf D, Stenson K et al. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol 1998;16:735-744.
44. Braakhuis B, Kegel A, Welters M. The growth inhibiting effect of docetaxel (Taxotere) in head and neck squamous cell carcinoma xenografts. Cancer Lett 1994;81:151-154.
45. Huttmann C, Eckardt A, Fokas K et al. Experimental chemotherapy of xenotransplanted oral squamous epithelial carcinoma: effectiveness of docetaxel (Taxotere) in the nude mouse model. Mund Kiefer Gesichtschir 1999;3:257-262.
46. Catimel G, Verweij J, Mattijssen V et al. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 1994;5:533-537.
47. Dreyfuss A, Clark J, Norris C et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 1996;14:1672-1678.
48. Couteau C, Chouaki N, Leyvraz S et al. A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. Br J Cancer 1999;81:457-462.
49. Inuyama Y, Kataura A, Togawa K et al. Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/ recurrent head and neck cancer. Gan To Kagaku Ryoho 1999;26:107-116.
50. Schöffski P, Catimel G, Planting AS et al. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group. Ann Oncol 1999;10:119-122.
51. Forastiere A, Glisson B, Murphy B et al. A phase II study of docetaxel and cisplatin in patients with locally advanced, recurrent, and/or metastatic squamous cell carcinoma of the head and neck not curable by standard therapy. Proc Am Soc Clin Oncol 1998;17:399a.
52. Baur M, Kienzer H, Schweiger J et al. First-line therapy in head and neck cancer with docetaxel and cisplatin. Ann Oncol 1998;9(suppl 4):75a.
53. Manzione L, Caponigro F, Massa E et al. A phase II study of docetaxel + cisplatin in locally advanced and metastatic squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 1999;18:398a.
54. Mel J, Rodriguez R, Constenla M et al. Phase II study of docetaxel and cisplatin as induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck. Preliminary results. Proc Am Soc Clin Oncol 1999;18:401a.
55. Colevas A, Busse P, Norris C et al. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial. J Clin Oncol 1998;16:1331-1339.
56. Colevas A, Norris C, Tishler R et al. Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol 1999;17:3503-3511.
57. Janinis J, Papadakou G, Panagos G et al. A phase II study of combined chemotherapy with docetaxel, cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the head and neck and nasopharyngeal cancer. Proc Am Soc Clin Oncol 1997;16:402a.
58. Schrijvers D, Van Herpen C, Kerger J et al. Phase I-II study with Docetaxel (D), Cisplatin(C) and 5-Fluorouracil (5-FU) in patients (pts) with locally advanced inoperable squamous cell carcinoma of the head and neck (SCCHN). Eur J Cancer 1999;35(suppl 4):164a.
59. Ando M, Watanabe T, Sasaki Y et al. A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer. Br J Cancer 1998;77:1937-1943.
60. Van Den Neste E, de Valeriola D, Kerger J et al. A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors. Clin Cancer Res 2000;6:64-71.
61. Petit T, Aylesworth C, Burris H et al. A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies. Ann Oncol 1999;10:223-229.
62. Fillipi M, Cupissol D, Calais G et al. A phase II study of docetaxel and 5-fluorouracil in metastatic or recurrent squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 1999;18:402a.
63. Airoldi M, Marchionatti S, Pedani F et al. Docetaxel + vinorelbine in recurrent heavily pretreated head and neck cancer patients. Proc Am Soc Clin Oncol 1999;18:401a.
64. Mauer A, Masters G, Haraf D et al. Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol 1998;16:159-164.
65. Koukourakis M, Bizakis J, Skoulakis C et al. Combined irinotecan, docetaxel and conventionally fractionated radiotherapy in locally advanced head and neck cancer. A phase I dose escalation study. Anticancer Res 1999;19:2305-2309.